With total confidence
You need clarity on what’s in your product—right down to trace-level impurities. Pharmaceutical products and APIs need low levels of impurities to be determined in the most difficult matrices – this can be an analytical challenge, requiring expertise and state-of-the art equipment. Whether you’re working to accelerate development timelines, address complex matrices, or stay ahead of evolving regulatory requirements, the stakes are high. Impurities can threaten therapeutic efficacy, trigger adverse reactions, or lead to costly compliance failures and delays in product release. That’s why you need a partner with both the scientific depth and analytical capability to uncover and resolve even the most elusive risks.
The Eurofins BioPharma Product Testing (BPT) network of laboratories offers world-leading support for the detection, characterisation, and quantification of impurities in pharmaceutical products and APIs. From process and degradation-related organic impurities to inorganic elements and genotoxic impurities, including nitrosamines, we help ensure you meet international requirements, including ICH Q3A, ICH Q3B, ICH Q3D, ICH Q6B, and ICH M7. We assist with determining the most suitable strategies for monitoring impurities and accelerating your drug development programmes or ensure product release.
Our services cover:
We combine state-of-the-art analytical instrumentation with the experience of our highly qualified teamstodetect ultra-low levels of impurities in even the most challenging matrices, using techniques such as HPLC, LC-MS/MS, GC-MS/MS, ICP-MS, and spectroscopic methods.
Our studies are designed to integrate seamlessly into your development lifecycle—whether you’re conducting early-stage assessments, confirming batch release specifications, or responding to regulatory queries. We support method development, validation, and routine testing under GMP conditions.
Qualitative/quantitative limits testing (AA and CHN).
Eurofins offers nitrosamine impurity analysis, as well as support testing for risk assessments.
Identification of organic compounds using modern mass spectrometry.
The screening involves molecule-specific methods. Five PFAS (PFOS, PFOA, PFHxS, PFNA, and HFPO-DA) are already monitored at Eurofins BPT using UHPLC-MS/MS, with 20 additional PFAS expected to be included by 2025. Performance testing is conducted on each matrix, along with PFAS estimation.
Qualitative/Quantitative limits testing (ICP and ICP/MS).
Chromatography equipment
Mass spectrometers
Detectors
Spectrophotometers